Whole genome sequencing-powered ctDNA sequencing for breast cancer detection
Top Cited Papers
Open Access
- 4 February 2025
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 36 (6) , 673-681
Abstract
No abstract availableKeywords
Funding Information
- Royal Marsden NHS Foundation Trust
- Breast Cancer Now (CTR-Q5-Y3)
- National Institute for Health and Care Research
- The Royal Marsden Cancer Charity
- Institute of Cancer Research
This publication has 27 references indexed in Scilit:
- Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyCancer Cell, 2023
- ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual diseasenpj Breast Cancer, 2023
- Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challengesBritish Journal of Cancer, 2022
- Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancerAnnals of Oncology, 2022
- Factors associated with late risks of breast cancer-specific mortality in the SEER registryBreast Cancer Research and Treatment, 2021
- Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survivalAnnals of Oncology, 2020
- Assessment of Molecular Relapse Detection in Early-Stage Breast CancerJAMA Oncology, 2019
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal CancerJAMA Oncology, 2019
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolutionNature, 2017
- Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancerBreast Cancer Research and Treatment, 2016